| Texto completo | |
| Autor(es): |
Glaser, Talita
;
Cappellari, Angelica Regina
;
Pillat, Micheli Mainardi
;
Iser, Isabele Cristiana
;
Wink, Marcia Rosangela
;
Oliveira Battastini, Ana Maria
;
Ulrich, Henning
Número total de Autores: 7
|
| Tipo de documento: | Artigo Científico |
| Fonte: | PURINERGIC SIGNALLING; v. 8, n. 3, p. 15-pg., 2012-09-01. |
| Resumo | |
Replacement of lost or dysfunctional tissues by stem cells has recently raised many investigations on therapeutic applications. Purinergic signaling has been shown to regulate proliferation, differentiation, cell death, and successful engraftment of stem cells originated from diverse origins. Adenosine triphosphate release occurs in a controlled way by exocytosis, transporters, and lysosomes or in large amounts from damaged cells, which is then subsequently degraded into adenosine. Paracrine and autocrine mechanisms induced by immune responses present critical factors for the success of stem cell therapy. While P1 receptors generally exert beneficial effects including anti-inflammatory activity, P2 receptor-mediated actions depend on the subtype of stimulated receptors and localization of tissue repair. Pro-inflammatory actions and excitatory tissue damages mainly result from P2X7 receptor activation, while other purinergic receptor subtypes participate in proliferation and differentiation, thereby providing adequate niches for stem cell engraftment and novel mechanisms for cell therapy and endogenous tissue repair. Therapeutic applications based on regulation of purinergic signaling are foreseen for kidney and heart muscle regeneration, Clara-like cell replacement for pulmonary and bronchial epithelial cells as well as for induction of neurogenesis in case of neurodegenerative diseases. (AU) | |
| Processo FAPESP: | 06/61285-9 - Bases moleculares da diferenciação de células-tronco e progenitoras neurais |
| Beneficiário: | Alexander Henning Ulrich |
| Modalidade de apoio: | Auxílio à Pesquisa - Temático |